Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JY231 in B-cell Acute Lymphoblastic Leukemia
NCT06514768Phase 1Recruiting
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JY231 in B cell acute lymphoblastic leukemia (B-ALL). Primary endpoints: Incidence of Treatment Related adverse events up to 12 months and Maximum Tolerated Dose up to 28 days. Started Jun 2024; status: recruiting.
02
Drugs
JY231
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06514768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06514768.